Last reviewed · How we verify
Dipivefrin (dipivefrine)
Dipivefrin, developed by Allergan, is a small molecule adrenergic receptor agonist targeting the alpha-2A adrenergic receptor. It is used to treat open-angle glaucoma, a condition characterized by increased intraocular pressure. Dipivefrin is a commercially available medication, with its original developer and current owner being Allergan. It was FDA-approved in 1980. As an adrenergic receptor agonist, dipivefrin works by stimulating the alpha-2A adrenergic receptor to decrease intraocular pressure.
At a glance
| Generic name | dipivefrine |
|---|---|
| Sponsor | AbbVie |
| Drug class | Adrenergic Receptor Agonist |
| Target | Alpha-2A adrenergic receptor |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1980 |
Approved indications
- Open-angle glaucoma
Common side effects
Drug interactions
- Inhalational Anesthetics
Key clinical trials
- Comparison of Phacoemulsification and Corneal Damage Between FLACS and Standard Phaco With Two Handpieces (NA)
- FS-LASIK Versus TransPRK for Mixed Astigmatism
- Toric Intraocular Lens Implantation in Pediatric Cataract (NA)
- Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear (NA)
- Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years
- Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry
- Capella Scientia Development Study
- Comparison of Two Different Optical Biometric Systems
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dipivefrin CI brief — competitive landscape report
- Dipivefrin updates RSS · CI watch RSS
- AbbVie portfolio CI